S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
Log in

NASDAQ:EPZM - Epizyme Stock Price, Forecast & News

$18.60
+0.38 (+2.09 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
$17.82
Now: $18.60
$19.30
50-Day Range
$10.30
MA: $14.00
$18.22
52-Week Range
$5.14
Now: $18.60
$19.30
Volume1.82 million shs
Average Volume808,279 shs
Market Capitalization$1.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.58
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.70 million
Book Value$2.94 per share

Profitability

Net Income$-123,630,000.00
Net Margins-468.53%

Miscellaneous

Employees124
Market Cap$1.69 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.


Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) issued its quarterly earnings data on Wednesday, October, 30th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.11. The biopharmaceutical company had revenue of $5.72 million for the quarter, compared to analysts' expectations of $5.50 million. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Epizyme.

What guidance has Epizyme issued on next quarter's earnings?

Epizyme issued an update on its third quarter earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of -$0.40 for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.48). The company issued revenue guidance of $5.7 million, compared to the consensus revenue estimate of $6.40 million.

What price target have analysts set for EPZM?

8 Wall Street analysts have issued 1 year price objectives for Epizyme's shares. Their forecasts range from $12.00 to $25.00. On average, they anticipate Epizyme's share price to reach $19.33 in the next year. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for Epizyme.

What is the consensus analysts' recommendation for Epizyme?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Has Epizyme been receiving favorable news coverage?

Media stories about EPZM stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Epizyme earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Epizyme.

Are investors shorting Epizyme?

Epizyme saw a decline in short interest in the month of October. As of October 15th, there was short interest totalling 7,280,000 shares, a decline of 12.7% from the September 15th total of 8,340,000 shares. Based on an average daily volume of 619,200 shares, the short-interest ratio is currently 11.8 days. Currently, 9.5% of the shares of the company are sold short. View Epizyme's Current Options Chain.

Who are some of Epizyme's key competitors?

What other stocks do shareholders of Epizyme own?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
  • Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)

Who are Epizyme's major shareholders?

Epizyme's stock is owned by many different of retail and institutional investors. Top institutional investors include Redmile Group LLC (9.48%), State Street Corp (3.14%), Millennium Management LLC (1.29%), Voya Investment Management LLC (0.72%), Rhenman & Partners Asset Management AB (0.49%) and California Public Employees Retirement System (0.30%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros and Robert B Bazemore. View Institutional Ownership Trends for Epizyme.

Which institutional investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, Redmile Group LLC, Rhenman & Partners Asset Management AB, Teacher Retirement System of Texas, Alps Advisors Inc. and Barclays PLC. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros and Robert B Bazemore. View Insider Buying and Selling for Epizyme.

Which institutional investors are buying Epizyme stock?

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, California Public Employees Retirement System, Metropolitan Life Insurance Co NY, California State Teachers Retirement System and Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $18.60.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.69 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

What is Epizyme's official website?

The official website for Epizyme is http://www.epizyme.com/.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (NASDAQ EPZM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  430 (Vote Outperform)
Underperform Votes:  332 (Vote Underperform)
Total Votes:  762
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel